Fundraising FoxDelos Capital — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(Founder)Kuo-Shyan Lin(Founder)David Perrin(Founder)
Co-investorsAndreessen HorowitzAscenta CapitalFrazier Life SciencesGeneral CatalystLightspeed Venture PartnersLongitude Capital+9 more
.png)
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Co-investorsaMoonRA CapitalBiotechnology Value FundSoleus Capital
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
BiotechSan Diego, US
Athena Countouriotis(Co-Founder, Chief Executive Officer)Mohammad Hirmand(Executive Officer)inPaolo Tombesi(Executive Officer)inScott Lipman(Executive Officer)inBrian Sun(Executive Officer)in
BoardCarl Gordon(Director)
Co-investorsForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)OrbiMedQuan Capital+6 more
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.
BiotechDigital HealthHealthtechMedical DevicesBurlington, US
Michael E. Mendelsohn(Founder and Chief Strategy Officer)in
Co-investorsBain CapitalAscenta CapitalDigitalis VenturesNew Enterprise Associates (NEA)Bain Capital Life SciencesBain Capital Tech Opportunities+4 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.